Joseph Antos, PhD, Wilson H. Taylor Scholar in Healthcare and Retirement Policy, American Enterprise Institute, says people need to accept and understand that Medicare will not pay for all healthcare expenses after the age of 65. It is necessary to realistically look at other payment alternatives.
Joseph Antos, PhD, Wilson H. Taylor Scholar in Healthcare and Retirement Policy, American Enterprise Institute, says people need to accept and understand that Medicare will not pay for all healthcare expenses after the age of 65. It is necessary to realistically look at other payment alternatives.
This video was taken on September 10 at AHIP's 2012 Medicare and Medicaid Conference in Washington, DC.
Angiogenesis Meeting to Highlight Latest in Technology, Translational Research, Clinical Trials
February 8th 2023The Angiogenesis, Exudation, and Degeneration 2023 meeting will be held virtually with a program focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Additional Results From POLARIX Study Show Improved PFS With No Reduction in HRQOL
January 29th 2023New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.
Read More
PolaR-ICE Effective as Second-line Treatment in DLBCL, Bridge to Autologous Stem Cell Transplant
January 28th 2023Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.
Read More
2 Clarke Drive
Cranbury, NJ 08512